<DOC>
	<DOCNO>NCT00207051</DOCNO>
	<brief_summary>This phase I dose escalation study determine safety , pharmacokinetics pharmacodynamics BMS-582664 combination full dose erbitux patient advance colorectal cancer receive 2 prior regimen metastatic colorectal cancer .</brief_summary>
	<brief_title>BMS-582664 Combination With Erbitux Patients With Advanced Gastrointestinal Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Diagnosis advance metastatic ( tumor spread ) gastrointestinal malignancy Feeling well cancer diagnosis ( ie lab work , infection , etc ) Available tumor tissue sample prior surgery Measurable disease scan 46 week since prior therapy recover effect prior therapy Men woman , age 18 Women must pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Advanced Gastrointestinal Malignancies</keyword>
</DOC>